SGSunitha Gurrala

Sunitha Gurrala

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sunitha Gurrala has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Response Surface Methodology in Spectrophotometric Estimation of Saxagliptin, Derivatization with MBTH and Ninhydrin

    by Sunitha Gurrala, Shiva Raj, Subrahmanyam Cvs, Durga Panikumar Anumolu, Swathi Naraparaju, Harika Nizampet

    Design of experiments assisted spectrophotometric methods have been established for the quantification of saxagliptin in pharmaceutical formulation via charge transfer complexation and Schiff’s base formation. Box-Behnken design was exploited in method-1, involved the measurement of absorbance of green/blue-colored complex (at 600 nm), formed by the reaction of saxagliptin with 3-methyl-2-benzothiazolinone hydrazone in the presence of ferric chloride. The central composite design was employed in method-2, involved the determination of absorbance of Ruhemann’s purple (at 585 nm), formed by the reaction of the primary amine group of saxagliptin with ninhydrin reagent in presence of sodium hydroxide. Optimization of reaction variables namely, reagent concentration (A), oxidizing agent/alkalinity (B) and reaction/heat time (C) was performed through response surface methodology for the response (Y) i.e. absorbance of colored compound. The reliability of both methods was investigated through validation as per International Council for Harmonisation guidelines. Saxagliptin executed linearity in the concentration range of 0.01-0.25 μg/mL and 1-10 μg/mL by method-1 and 2. A high value of molar absorptivity, low values of Sandell’s sensitivity and limit of detection/limit of quantification divulges the good sensitivity methods. The % assay of saxagliptin in the marketed formulation was found to be 100.27 and 99.86 by method-1 and method-2, respectively. The proposed eco-friendly and economical methods can be routinely employed in quality control for the analysis of saxagliptin in the pharmaceutical dosage forms.


  • APPLICATION OF EMISSION INTENSITY IN QUANTIFICATION AND FORCED DEGRADATION STUDIES OF MESALAMINE

    by Sunitha Gurrala, Panikumar D. Anumolu, Vasavi Panchakatla, Radhagayathri Achanta, Rajesh Chakka, Veda Maddala

    A simple and sensitive spectrofluorimetric method has been developed for the estimation of mesalamine (MES). Linearity was obeyed in the range of 0.1-2.5 µg/mL in distilled water as solvent at an emission wavelength (λem) of 501 nm after excitation (λex) at 332 nm, with a good correlation coefficient of 0.999. The limit of detection and limit of quantification for this method were 0.05 and 0.1 µg/mL, respectively. The developed method was statistically validated as per ICH guidelines. The percentage relative standard deviation values were found to be less than 2 for accuracy and precision studies. The assay results obtained were in good agreement with the labeled amounts of the marketed formulations. This validated method was extended to study the degradation behavior of mesalamine in various conditions such as acid, alkaline, oxidative, thermal, and UV effects. Although there was no degradation observed in oxidative, thermal, UV effect, 41.9 % and 11.6 % amount was degraded in acid and alkaline media, respectively. The proposed method was effectively applied to routine quality control analysis of mesalamine in bulk and marketed formulations.

  • DOMINATED RP-HPLC METHOD FOR QUALITY CONTROL OF TERNARY PHARMACEUTICAL FORMULATION: GUAIFENESIN/LEVOCETIRIZINE/ AMBROXOL HCL AND STABILITY STUDIES

    by Anumolu P.D, Sunitha G, Swathi N, Sri Manaswini, Radha Gayatri A, Sunayana Reddy M

    The present investigation was aimed to establish a liquid chromatographic method for simultaneous quantification of guaifenesin, levocetirizine and ambroxol HCl in ternary fixed dosage form. The three drugs were swiftly resolved using ODS C18 reverse phase column with mobile phase consisting of ammonium phosphate buffer, pH 4.5: acetonitrile (60:40, v/v) at a flow rate of 1.0 mL/min and UV detection at 236 nm. The retention time values were 2.231, 2.772 and 6.309 min, respectively, for guaifenesin, levocetirizine and ambroxol HCl. The response was a linear function of analyte over the concentration range of 12.5-75 µg/mL, 0.625-3.750 µg/mL and 3.75-22.5 µg/mL with correlation co-efficient value of 0.999. Maximum recovery (99.12-101.2 %) was obtained in ternary liquid oral formulation (Leoriv plus syrup). Three drugs were well resolved from their degradation products and net degradation was calculated in acid hydrolysis, base hydrolysis, oxidation, thermal and UV conditions. The proposed method enables the simultaneous quantification of guaifenesin, levocetirizine and ambroxol HCl in routine QC laboratories.

  • Quality-by-Design Approach for Chromatographic Analysis of Metformin, Empagliflozin and Linagliptin

    by Sunitha Gurrala, Shiva Raj, Subrahmanyam Cvs, Panikumar Durga Anumolu

    New analytical quality by design-oriented HPLC method with multiple response optimization (Derringer’s desirability function) was demonstrated for simultaneous analysis of three antidiabetic drugs (metformin hydrochloride/empagliflozin/linagliptin) in a fixed-dose combination. Central composite design was employed for systematic optimization of critical method parameters, namely, % organic phase (X1), aqueous phase pH (X2) and flow rate (X3) while resolution, capacity factor and theoretical plate number as critical analytical attributes. Effective chromatographic separation of title analytes was accomplished on Std. Discovery C18 column at 30°C with mobile phase comprising acetonitrile: phosphate buffer pH 5 (38:62% v/v), pumped at a flow rate of 1 mL/min by isocratic elution pattern and UV detection at 222 nm. The model is rectilinear in the range of 1.0–200, 0.2–40 and 0.1–20 μg/mL at retention times of 3.04, 3.93 and 5.99 min for metformin, empagliflozin and linagliptin, respectively. The method obeyed all validation parameters of ICH Q2(R1) guidelines. The proposed HPLC method was highly robust for method transfer, regulatory flexibility within design space and can be used for assay of pharmaceutical dosage forms comprising these analytes. The proposed method was applied for stability studies of drugs under various stress conditions.


  • Open Access

    Spectrophotometric estimation of linagliptin using ion-pair complexation and oxidative coupling reactions – A green approach

    by Sunitha Gurrala, Panikumar Durga Anumolu, Sahitya Menkana, Nikitha Gandla, Keerthi Toddi

    Background: Two specific spectrophotometric methods (visible region) have been established using water as a solvent and validated for the analysis of linagliptin in API and pharmaceutical dosage forms. Materials and Methods: Method-A is established on th.


  • Open Access

    Analytical Quality by Design Assisted HPLC Method for Quantification of Canagliflozin/ Metformin and Stability Studies

    by Sunitha Gurrala, Shivaraj Shivaraj S, Subrahmanyam Cvs Subrahmanyam, Panikumar Durga Anumolu, Gowthami Saraf, Shivaraj


  • Open Access

    Development of a Discriminative and Biorelevant Dissolution Test Method for Atorvastatin/Fenofibrate Combination with Appliance of Derivative Spectrophotometry

    by Panukumar Durga Anumolu, Sunitha Gurrala, Subrahmanyam Chavali Venkata Satya, Santoshi Vani Polisetty, Anjana Ravindran, Radhagayathri Achanta

    Nowadays, the market is flooded with combinations of drugs in various dosage forms, but there is a lack of official methods to quantify them. A single dissolution test method for the analysis of combined dosage form is preferred for simplification of quality control testing. If the developed dissolution medium mimics the biorelevant and discriminating dissolution procedure for drug products with limited drug aqueous solubility it is a useful tool for qualitative forecasting of the in vivo behavior of formulations. Dissolution profiles were evaluated for atorvastatin and fenofibrate in capsules, using a paddle-type United States Pharmacopeia dissolution apparatus in 900 mL of medium at 50 rpm and 37±0.5°C. The best medium was 900 mL of 0.5% w/v sodium lauryl sulfate. The cumulative % dissolution was more than 85% within 45 min for marketed tablets. The proposed dissolution test conditions have discriminative power, dissimilarity factor (f1) values are low (12-16%), and similarity (f2) factor values are also low (45-48%). Hence the use of 0.5% w/v sodium lauryl sulfate solution is justified. The dissolution method was validated (% relative standard deviation max 281 nm and 296 nm, respectively, for atorvastatin and fenofibrate) in acetate buffer, pH 2.8 solution.


  • Degradation Kinetics, In Vitro Dissolution Studies, and Quantification of Praziquantel, Anchored in Emission Intensity by Spectrofluorimetry

    by Panikumar D. Anumolu, Sunitha Gurrala, Ceema Mathew, Vasavi Panchakatla, Veda Maddala

    Objectives: A simple, rapid, specific, and highly sensitive ecofriendly spectrofluorimetric method has been developed for the quantification of praziquantel. Materials and Methods: A linear relationship was found between fluorescence intensity and praziquantel concentration in the range of 1-20 mu g/mL in water at emission wavelength of 286 nm after excitation wavelength at 263 nm with a good correlation coefficient (0.999). Results: The proposed method was validated according to International Conference on Harmonization guidelines and statistical analysis of the results revealed high accuracy and good precision with the percentage relative standard deviation values less than 2. The detection and quantification limits were 0.27 and 0.81 mu g/mL, respectively. The proposed method was extended to investigate the stability of the drug and its degradation kinetics in the presence of acidic, alkaline, and oxidative conditions. Conclusion: The method was utilized for in vitro dissolution studies of praziquantel tablet formulation. The suggested procedures could be used for the assessment of praziquantel in drug substance and drug products as well as in the presence of its degradation products.


  • Quantification of Tamsulosin Hydrochloride and Solifenacin Succinate by Discriminative Derivative Synchronous Emission Spectroscopy

    by Swathi Naraparaju, Pani Kumar D. Anumolu, Sunitha Gurrala, Rajeshwari Galennagari

    The present study was undertaken with the objective to develop and validate a simple spectrofluorimetric method for the simultaneous quantification of tamsulosin hydrochloride and solifenacin succinate. First-derivative synchronous spectrofluorimetry was attempted for the simultaneous quantification of the analytes. Tamsulosin hydrochloride was quantified at a wavelength of 322 nm (zero-crossing wavelength point of solifenacin succinate) and solifenacin succinate was measured at 570 nm (zero-crossing wavelength point of tamsulosin hydrochloride). Calibration plots were constructed over the concentration range of 2-10 µg/mL for tamsulosin hydrochloride and 30-150 µg/mL for solifenacin succinate. The method gave satisfactory results when it is validated for linearity, specificity, accuracy, precision, LOD and LOQ as per the ICH guidelines. The assay values in the commercial formulation were found to be in the percentage range of 95.0 for tamsulosin hydrochloride and 103.5 for solifenacin succinate by the proposed method. These results were well in agreement with their label claim. The proposed synchronous analytical method can be employed for routine quality control analysis of tamsulosin hydrochloride/solifenacin succinate in tablet dose forms.


  • Open Access

    Quantification and stress degradation studies of cefepime/tazobactam in dry injection form by an RP-HPLC method

    by Ramakrishna Kommana, Gouthami Kannabattula, Sunitha Gurrala, Venkat Raj Yeradesi, Panikumar Anumolu Durga

    A simple, specific, precise, accurate, linear, rapid, economic and validated stability indicating an RP-HPLC method for the simultaneous quantification of cefepime and tazobactam in a dry injection dosage form has been developed. Separation was performed on a 5 µm ACE C18column with phosphate buffer, pH adjusted to 4.5 with phosphoric acid: methanol (70:30) at a flow rate of 1 mL/min and at a temperature of 25 °C. Regression analysis showed linearity at a detector wavelength of 290 nm in the range of 200-600 μg/mL for cefepime and 25-75 μg/mL for tazobactam. All of the analytes were adequately resolved with acceptable tailing. The percentage content found for cefepime was 99.98% and of tazobactam was 99.49% in the parenteral formulation. The method was validated in terms of linearity, precision, accuracy, specificity, robustness and system suitability according to ICH guidelines. Stress degradation studies were performed on the placebo and drug products, drugs of interest were well resolved from the degradation products. The developed method was effectively applied for the simultaneous quantification of cefepime and tazobactam in a dry injection formulation.